Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer

Table 2

First-line drug therapies and median overall survival (OS) times with respective 95% confidence intervals (CIs).

Drug	No. of patients (%)	Median OS (95% CI) (months)
No drug therapy	453 (46.4%)	3.0 (2.6–3.4)
Sunitinib	278 (28.5%)	20.1 (15.7–24.5)
Interferon single	112 (11.5%)	14.5 (8.5–20.6)
Interferon + vinblastine	58 (5.9%)	15.6 (12.6–18.7)
Interferon + capecitabine	16 (1.6%)	13.4 (1.8–25.0)
Temsirolimus	16 (1.6%)	10.8 (8.5–13.1)
Sorafenib	15 (1.5%)	19.9 (0.0–44.5)
Pazopanib	7 (0.7%)	19.7 (16.0–23.5)
Bevacizumab	7 (0.7%)	15.4 (8.9–22.0)
Bevacizumab + interferon	3 (0.3%)	54.5 (4.1–104.8)
Regorafenib	3 (0.3%)	51.3 (0.0–125.9)
Vinblastine	2 (0.2%)	1.5
Everolimus	1 (0.1%)	8.5
Vinblastine + bevacizumab	1 (0.1%)	9.2
Etoposide	1 (0.1%)	3.3
Ifosfamide + doxorubicin	1 (0.1%)	18.3
Capecitabine	1 (0.1%)	6.4
Erlotinib	1 (0.1%)	10.3
Ifosfamide and mesna + adriamycin	1 (0.1%)	6.1
Overall	977 (100.0%)	8.7 (7.5–9.9)